- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02067117
Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Post-Marketing, Multicentre, Open, Randomized Phase 4 Clinical Study. Subjects who gave voluntary written informed consent to participate in the study were screened for eligibility in the study, and those who met the eligibility criteria were randomized in the investigational group.
An investigator assessed the effectiveness (immunogenicity) and safety of the study vaccine in each subject during his/her participation in the study.
Subjects were randomized (Visit 1) into the investigational group according to a randomization table previously generated, and were vaccinated with influenza split vaccine, 'GC FLU®Pre-filled Syringe Injection' and 'GC FLU®Injection'.
12 Assessments for HI titre to each strain of influenza were performed at Visit 1 (pre-vaccination), and at Visit 3 (21 days after vaccination) for the efficacy (immunogenicity) evaluation [Picture 1].For the safety assessment, subject diaries were handed out to subjects, who were instructed to record any adverse event emerging ager the receipt of study vaccine.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults≥ 18 and < 65years of age who can be followed up for 21 days.
Depending on the part of the study that a subject was going to participate, age criteria were further divided as follows:
Lot-to-lot consistency study [PART A]: ≥ 18 to < 65 years of age Annual clinical trial [PART B]: ≥ 18 to < 65 years of age [adults]
65 years of age [elderly population]
- Subjects who gave voluntary written consent to participate in the study, and are able to comply with the study requirements.
Exclusion Criteria:
- Subjects with a known hypersensitivity of allergic reaction to eggs or egg products, to chicken or chichenproducts, to any component of the study vaccine, neomycin or gentanicin.
- Subjects with immune system disorders, including immune deficiency disease.
- Subjects with a history of Guillain-Barre syndrome.
- Subjects with severe chronic disease (e.g., cardiovascular disease except for controlled hypertension, respiratory disease, metabolic disease, renal dysfunction or hemoglobinopathy, etc.) who in the investigator's opinion may have difficulty in participating in the study.
- Subjects with haemophilia or receiving a treatment with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection.
- Subjects who had acute fever with the body temperature exceeding 38.0 °C within 72 hours before vaccination with the study drug.
- Subjects who had received other vaccinations within 7 days before vaccination with the study drug, or those who had another vaccination scheduled during the study.
- Subjects who had received immunosuppressant or immune modifying drug within 3 months before vaccination with the study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: influenza split vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GMT (Geometric Mean Titre) of HI antibody titrebefore vaccination (Day 0) and after vaccination
Time Frame: Day 21
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of subjects achieving seroconversion for HI antibody (Seroconversion rate)
Time Frame: Day21
|
Day21
|
GMT (Geometric Mean Titre) of HI antibody titre before vaccination (Day 0) and after vaccination
Time Frame: Day 21
|
Day 21
|
Solicited local adverse events (topical symptoms) and solicited general adverse events (systemic symptoms) occurring from the date of vaccination until 6 days after vaccination
Time Frame: Day 6
|
Day 6
|
The percentage of subjects achieving HI antibody titre ≥ 1:40 following the receipt of vaccination (Seroprotection rate).
Time Frame: Day21
|
Day21
|
The percentage of subjects achieving seroconversion for HI antibody (Seroconversion rate)
Time Frame: Day 21
|
Day 21
|
The percentage of subjects achieving HI antibody titre ≥ 1:40 following the receipt of vaccination(Seroprotection rate).
Time Frame: Day 21
|
Day 21
|
Unsolicited adverse events occurring from the date of vaccination until 21 days after vaccination
Time Frame: Day 21
|
Day 21
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCFLU_P4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Influenza
-
SK Chemicals Co., Ltd.CompletedPrevention of InfluenzaKorea, Republic of
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Completed
-
University Hospital, GhentCEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaboratorsCompletedPrevention of InfluenzaBelgium
-
Janssen Vaccines & Prevention B.V.CompletedInfluenza, Human Prevention | Respiratory Syncytial Viruses PreventionUnited States
-
TakedaWithdrawnInfluenza PreventionJapan
-
TakedaCompletedPandemic Influenza PreventionJapan
-
Sinovac Biotech Co., LtdCenters for Disease Control and Prevention, ChinaCompletedPrevention | Pandemic Influenza | Pandemic Influenza VaccineChina
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
Janssen Vaccines & Prevention B.V.Biomedical Advanced Research and Development AuthorityActive, not recruitingInfluenza PreventionUnited States
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina
Clinical Trials on GC FLU® Injection, GC FLU® Pre-filled Syringe Injection
-
Green Cross CorporationCompleted
-
Green Cross CorporationCompletedInfluenzaKorea, Republic of
-
Green Cross CorporationCompleted
-
Il-Yang Pharm. Co., Ltd.Not yet recruiting
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedHealthy Adult SubjectsChina
-
Il-Yang Pharm. Co., Ltd.CompletedInfluenza, HumanKorea, Republic of
-
Institute of Clinical Research and Clinical Trial...Green Cross CorporationCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedGrowth Hormone Deficiency
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsNot yet recruiting
-
Yuhan CorporationRecruitingAllergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible UrticariaKorea, Republic of